GlassScriptPhysician profile
Thomas Knightly
NPI 1447771282
$5,750.25
in general payments reported to CMS, 2019-2025
15 companies · $2,505 in 2025
The $2,505 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,000 · 2023: $49.08 · 2024: $197 · 2025: $2,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,750.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $3,049.08 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $935.55 | 2024-2025 | Spravato |
| Abbvie INC. | $427.20 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $398.77 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $135.59 | 2024-2025 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $120.52 | 2025 | Rexulti |
| Corium, LLC | $107.10 | 2025 | Azstarys |
| Neurocrine Biosciences, INC. | $98.82 | 2025 | |
| Tris Pharma INC | $98.69 | 2024-2025 | Dyanavel Xr |
| Alkermes, INC. | $79.91 | 2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $77.23 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $73.58 | 2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $71.36 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $54.97 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $21.88 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Knightly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.